Highlighting the critical role of DNL in MASH are findings with pharmacological inhibitors of cytosolic citrate (123, 124), ACLY (125), ACC (126, 127), or fatty acid synthase (FAS) (128, 129), which exert favorable activities on reducing DNL and lowering steatosis in preclinical models and, in some cases, clinical populations (reviewed in refs. 96, 130) (Figure 3). Here, FAS is linked to steatosis.